The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

ViroPharma to Participate in Two December Healthcare Investor Conferences

Wednesday, November 24, 2010

ViroPharma to Participate in Two December Healthcare Investor Conferences11:00 EST Wednesday, November 24, 2010EXTON, Pa., Nov. 24, 2010 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that William Roberts, vice president, corporate communications of ViroPharma, will present at the 22nd Annual Piper Jaffray Healthcare Conference at 12:30 P.M. ET on Wednesday, December 1, 2010.  The conference is being held at the New York Palace Hotel.Vincent Milano, president and chief executive officer of ViroPharma, will present at the 2010 Deutsche Bank BioFest Conference at 2:05 P.M. ET on Wednesday, December 15, 2010.  The conference is being held at the Four Seasons Hotel in Boston.ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.About ViroPharma IncorporatedViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze® (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx).  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile. ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.SOURCE ViroPharma IncorporatedFor further information: Robert A. Doody Jr., Assistant Director, Investor Relations, ViroPharma Incorporated, +1-610-321-6290